Ultra‐low‐dose IL‐2 administration has good tolerability and drives Treg population expansion in vivo [11] and may be linked to a decreased incidence of infections and GVHD after HLA‐matched related or unrelated allo‐HSCT [12]. This evidence concerns the gene IL2 and graft versus host disease.